DYNREMY Trademark

Trademark Overview

On Thursday, December 22, 2016, a trademark application was filed for DYNREMY with the United States Patent and Trademark Office. The USPTO has given the DYNREMY trademark a serial number of 87278377. The federal status of this trademark filing is CANCELLED - SECTION 8 as of Friday, May 30, 2025. This trademark is owned by CHUGAI SEIYAKU KABUSHIKI KAISHA (Chugai Pharmaceutical Co., Ltd.). The DYNREMY trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of neuromyelitis optica spectrum disorder
dynremy

General Information

Serial Number87278377
Word MarkDYNREMY
Filing DateThursday, December 22, 2016
Status710 - CANCELLED - SECTION 8
Status DateFriday, May 30, 2025
Registration Number5609437
Registration DateTuesday, November 20, 2018
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, August 29, 2017

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of neuromyelitis optica spectrum disorder

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code2 - Sec. 8 - Entire Registration
Class Status DateFriday, May 30, 2025
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameCHUGAI SEIYAKU KABUSHIKI KAISHA (Chugai Pharmaceutical Co., Ltd.)
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressTokyo
JP
Party NameCHUGAI SEIYAKU KABUSHIKI KAISHA (Chugai Pharmaceutical Co., Ltd.)
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressTokyo
JP
Party NameCHUGAI SEIYAKU KABUSHIKI KAISHA (Chugai Pharmaceutical Co., Ltd.)
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressTokyo
JP

Trademark Events

Event DateEvent Description
Thursday, January 5, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, April 21, 2017TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, April 21, 2017CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, December 27, 2016NEW APPLICATION ENTERED
Wednesday, March 22, 2017ASSIGNED TO EXAMINER
Wednesday, March 22, 2017NON-FINAL ACTION WRITTEN
Wednesday, March 22, 2017NON-FINAL ACTION E-MAILED
Wednesday, March 22, 2017NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, April 21, 2017TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, July 18, 2017ASSIGNED TO LIE
Thursday, July 20, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, April 24, 2017SUSPENSION LETTER WRITTEN
Monday, April 24, 2017LETTER OF SUSPENSION E-MAILED
Monday, April 24, 2017NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Monday, June 12, 2017TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Wednesday, July 19, 2017CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, July 19, 2017TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, August 29, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, October 24, 2017NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, April 12, 2018SOU EXTENSION 1 FILED
Thursday, April 12, 2018SOU EXTENSION 1 GRANTED
Tuesday, October 16, 2018NOTICE OF ALLOWANCE CANCELLED
Tuesday, October 16, 20181(B) BASIS DELETED; PROCEED TO REGISTRATION
Wednesday, August 9, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, August 29, 2017PUBLISHED FOR OPPOSITION
Thursday, April 12, 2018SOU TEAS EXTENSION RECEIVED
Thursday, April 12, 2018TEAS POST PUBLICATION AMENDMENT RECEIVED
Saturday, April 14, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, November 20, 2018REGISTERED-PRINCIPAL REGISTER
Monday, November 20, 2023COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Friday, May 30, 2025CANCELLED SEC. 8 (6-YR)

Related Keywords

dynremy spectrum disorder optica neuromyelitis preparations treatment pharmaceutical